GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » LHC Group Inc (NAS:LHCG) » Definitions » Sloan Ratio %

LHC Group (LHC Group) Sloan Ratio % : 1.67% (As of Dec. 2022)


View and export this data going back to 2005. Start your Free Trial

What is LHC Group Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

LHC Group's Sloan Ratio for the quarter that ended in Dec. 2022 was 1.67%.

As of Dec. 2022, LHC Group has a Sloan Ratio of 1.67%, indicating the company is in the safe zone and there is no funny business with accruals.


LHC Group Sloan Ratio % Historical Data

The historical data trend for LHC Group's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LHC Group Sloan Ratio % Chart

LHC Group Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.02 3.42 -13.50 28.45 1.67

LHC Group Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.45 31.27 26.42 11.30 1.67

Competitive Comparison of LHC Group's Sloan Ratio %

For the Medical Care Facilities subindustry, LHC Group's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LHC Group's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, LHC Group's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where LHC Group's Sloan Ratio % falls into.



LHC Group Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

LHC Group's Sloan Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2022 )-Cash Flow from Operations (A: Dec. 2022 )
-Cash Flow from Investing (A: Dec. 2022 ))/Total Assets (A: Dec. 2022 )
=(39.871-49.974
--58.36)/2896.957
=1.67%

LHC Group's Sloan Ratio for the quarter that ended in Dec. 2022 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2022 )
=(39.871-49.974
--58.36)/2896.957
=1.67%

LHC Group's Net Income for the trailing twelve months (TTM) ended in Dec. 2022 was 19.454 (Mar. 2022 ) + 10.584 (Jun. 2022 ) + 17.309 (Sep. 2022 ) + -7.476 (Dec. 2022 ) = $40 Mil.
LHC Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2022 was -64.956 (Mar. 2022 ) + 62.668 (Jun. 2022 ) + 12.326 (Sep. 2022 ) + 39.936 (Dec. 2022 ) = $50 Mil.
LHC Group's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2022 was -6.542 (Mar. 2022 ) + -22.266 (Jun. 2022 ) + -3.186 (Sep. 2022 ) + -26.366 (Dec. 2022 ) = $-58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LHC Group  (NAS:LHCG) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2022, LHC Group has a Sloan Ratio of 1.67%, indicating the company is in the safe zone and there is no funny business with accruals.


LHC Group Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of LHC Group's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


LHC Group (LHC Group) Business Description

Traded in Other Exchanges
N/A
Address
901 Hugh Wallis Road South, Lafayette, LA, USA, 70508
LHC Group Inc provides post-acute health care services to patients through its home nursing agencies, community-based services agencies, hospice agencies, and long-term acute care hospitals. The company's home health service locations offer a wide range of services, including skilled nursing, medically-oriented social services and physical, occupational, and speech therapy. Its hospices provide end-of-life care to patients with terminal illnesses through interdisciplinary teams of physicians, nurses, home health aides, counselors, and volunteers. Its other service segments are Home and community based, Facility-based, Hospice and Healthcare Innovations. The company derives most of its revenues from the Home health services.
Executives
Nicholas Iii Gachassin officer: EVP, General Counsel 901 HUGH WALLIS ROAD SOUTH, LAFAYETTE LA 70508
Dale Mackel other: CFO 901 HUGH WALLIS ROAD S, LAFAYETTE LA 70508-2511
Reed W Earl Iii director 9510 OMSBY SLATION ROAD, STE 300, LOIISVILLE KY 40223
Kimberly S Seymour other: SVP, Chief Accounting Officer 901 HUGH WALLIS ROAD S, LAFAYETTE LA 70508
Tricia Nguyen other: EVP, Chief Medical Officer 1801 KIRA COURT, ARLINGTON TX 76006
Mcquiddy Collin other: SVP, Chief Accounting Officer 901 HUGH WALLIS ROAD S, LAFAYETTE LA 70508
Donald Dwayne Stelly officer: Senior Vice President 420 WEST PINHOOK ROAD, SUITE A, LAFAYETTE LA 70503
John L Indest director, officer: COO of Home, Senior V.P. 420 WEST PINHOOK ROAD, SUITE A, LAFAYETTE LA 70503
Ronald T Nixon director 1375 ENCLAVE PKWY, HOUSTON TX 77077
Keith G Myers director, 10 percent owner, officer: CEO and President 901 HUGH WALLIS RD S, LAFAYETTE LA 70508
Joshua L. Proffitt officer: Executive Vice President 901 HUGH WALLIS ROAD SOUTH, LAFAYETTE LA 70508
Teri G. Fontenot director 18933 EAST PINNACLE CIRCLE, BATON ROUGE LA 70634
Tyree G Wilburn director
Jeff Reibel officer: See Remarks 9510 ORMSBY STATION ROAD, SUITE 300, LOUISVILLE KY 40223
Bruce D Greenstein officer: Chief Innovation Officer 901 HUGH WALLIS ROAD SOUTH, LAFAYETTE LA 70508